Gilead Sciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GILD Nasdaq 2830 www.gilead.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gilead Sciences, Inc.

Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak - Dec 12th, 2025 2:05 pm
Kymera's Eczema Drug Gets Fast Track Designation in the United States - Dec 12th, 2025 8:30 am
Arcus cancels work on Gilead-partnered cancer combo after trial setback - Dec 12th, 2025 4:47 am
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight - Dec 11th, 2025 3:31 pm
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment - Dec 11th, 2025 5:44 am
3 Profitable Stocks We Keep Off Our Radar - Dec 10th, 2025 9:36 pm
New Study: Integrative Therapy and Nurse Navigation Reduce Treatment Side Effects for 75% of Black Breast Cancer Patients; 85% Report Lower Distress - Dec 10th, 2025 1:00 pm
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) - Dec 10th, 2025 9:28 am
Here's What We Like About Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend - Dec 10th, 2025 3:52 am
Mirum to buy Bluejay for up to $820m in rare liver disease push - Dec 9th, 2025 7:42 am
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Dec 9th, 2025 6:30 am
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025 - Dec 7th, 2025 6:00 am
Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates - Dec 7th, 2025 1:10 am
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma - Dec 6th, 2025 12:00 pm
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 - Dec 6th, 2025 12:00 pm
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Dec 4th, 2025 7:00 am
3 Unpopular Stocks We Think Twice About - Dec 3rd, 2025 9:37 pm
Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence - Dec 3rd, 2025 8:15 pm
Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment? - Dec 3rd, 2025 3:13 pm
Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue? - Dec 3rd, 2025 9:30 am